# Alzheimer's and Dementia Care: History

## Historical Development

### Pre-Modern Era

For most of human history, cognitive decline in old age was accepted as a normal part of aging, described as "senility" or "dotage" rather than as a disease requiring medical attention.

| Period | Understanding |
|--------|---------------|
| Ancient times | "Senility" as natural aging |
| 19th century | "Dementia" as medical term |
| Pre-1900 | Institutional care in asylums |
| Early 1900s | First scientific investigations |

### The Discovery of Alzheimer's Disease

| Year | Event | Significance |
|------|-------|--------------|
| 1901 | Dr. Alois Alzheimer examines Auguste Deter | First documented case |
| 1906 | Alzheimer presents brain pathology findings | Identifies plaques and tangles |
| 1910 | Emil Kraepelin names "Alzheimer's disease" | Establishes as distinct condition |
| 1960s | Alzheimer's viewed as rare, early-onset only | "Senile dementia" considered separate |
| 1976 | Robert Katzman editorial in *Archives of Neurology* | Argues senile dementia = Alzheimer's |

### The Katzman Revolution (1970s)

Dr. Robert Katzman's 1976 argument that Alzheimer's disease and "senile dementia" were the same condition transformed understanding and advocacy:

| Before 1976 | After 1976 |
|-------------|------------|
| "Senility" is normal aging | Dementia is a disease |
| Only young people get Alzheimer's | All ages affected |
| Nothing to be done | Research needed |
| No advocacy movement | Advocacy emerges |
| No dedicated funding | Push for federal research |

## Key Turning Points

### 1970s-1980s: Recognition and Advocacy

| Year | Development | Impact |
|------|-------------|--------|
| 1974 | NIA established at NIH | Federal aging research focus |
| 1979 | Jerome Stone founds ADRDA (now Alzheimer's Association) | National advocacy organization |
| 1980 | First NIA Alzheimer's research funding | $13 million initial investment |
| 1984 | Alzheimer's Disease Research Centers established | NIH network of 30 centers |
| 1986 | Alzheimer's Association 1st Annual Report | Nationwide disease awareness |

### 1990s: Genetics and Drug Development

| Year | Development | Impact |
|------|-------------|--------|
| 1993 | APOE Îµ4 gene identified as risk factor | First genetic link |
| 1993 | Tacrine (Cognex) approved | First FDA-approved treatment |
| 1994 | Ronald Reagan announces diagnosis | Celebrity disclosure increases awareness |
| 1996 | Donepezil (Aricept) approved | Still-used symptomatic treatment |
| 1999 | Amyloid hypothesis gains dominance | Shapes research for decades |

### 2000s: Expanded Focus

| Year | Development | Impact |
|------|-------------|--------|
| 2000 | Galantamine and rivastigmine approved | More treatment options |
| 2003 | Memantine approved | Different mechanism of action |
| 2004 | Alzheimer's Disease Neuroimaging Initiative (ADNI) | Major biomarker research |
| 2008 | NIH State of the Science conference | Identified prevention research gaps |

### 2010s: National Priority Status

| Year | Development | Impact |
|------|-------------|--------|
| 2011 | National Alzheimer's Project Act signed | First comprehensive federal strategy |
| 2012 | First National Plan to Address Alzheimer's Disease | Sets goal to prevent/treat by 2025 |
| 2014 | NIH funding begins major increase | From $500M toward $2B+ |
| 2015 | Breakthrough Status for drugs | Accelerated FDA pathway |
| 2018 | BOLD Infrastructure for Alzheimer's Act | Public health approach |

### 2020s: Treatment Breakthroughs and Controversies

| Year | Development | Impact |
|------|-------------|--------|
| 2021 | Aducanumab (Aduhelm) approved | First amyloid-targeting drug; controversial |
| 2021 | Medicare limits coverage of Aduhelm | Cost and efficacy concerns |
| 2023 | Lecanemab (Leqembi) approved | Modest efficacy; better evidence |
| 2023 | Medicare covers Leqembi (with CED) | Coverage with evidence development |
| 2024 | Donanemab approval expected | Another amyloid-targeting drug |

## Evolution of Care Models

### Institutional Care History

| Era | Model | Characteristics |
|-----|-------|-----------------|
| Pre-1965 | Almshouses, asylums | Custodial, undifferentiated |
| 1965-1980s | Nursing homes | Medicaid-funded, medical model |
| 1980s-1990s | Special care units | Dementia-specific, secured |
| 1990s-2000s | Assisted living memory care | Less institutional |
| 2000s-present | Person-centered care | Individualized, home-like |

### Community Care Development

| Period | Development |
|--------|-------------|
| 1970s | Adult day services emerge |
| 1980s | Respite care programs begin |
| 1990s | Alzheimer's Association local services expand |
| 2000s | Home care agencies offer dementia specialty |
| 2010s | Technology for aging in place |
| 2020s | Telehealth for caregivers |

### Philosophy of Care Evolution

| Era | Dominant Approach |
|-----|-------------------|
| Pre-1980s | Custodial, sedation common |
| 1980s | Behavioral management focus |
| 1990s | Special care unit movement |
| 2000s | Person-centered care emerges |
| 2010s | Eden Alternative, Green House |
| Present | Dementia-friendly communities |

## Research History

### The Amyloid Hypothesis Era (1990s-Present)

The dominant research paradigm has focused on amyloid protein accumulation:

| Period | Focus | Results |
|--------|-------|---------|
| 1990s | Basic amyloid research | Genetic discoveries |
| 2000s | Amyloid-targeting vaccines | Clinical failures |
| 2010s | Anti-amyloid antibodies | Mixed results |
| 2020s | First approvals | Modest efficacy |

### Failed Trials and Paradigm Challenges

| Drug/Trial | Year | Outcome |
|------------|------|---------|
| AN-1792 vaccine | 2002 | Halted (brain inflammation) |
| Bapineuzumab | 2012 | Failed Phase III |
| Solanezumab | 2016 | Failed Phase III |
| Aducanumab | 2019 | Trials halted, then unhalted |
| Multiple BACE inhibitors | 2018-2019 | All failed |

### Emerging Research Directions

| Focus | Rationale |
|-------|-----------|
| Tau protein | Alternative pathology target |
| Neuroinflammation | Immune system role |
| Vascular factors | Blood flow, cardiovascular |
| Prevention trials | Lifestyle, earlier intervention |
| Combination approaches | Multiple targets |

## Caregiver Recognition History

### Evolution of Caregiver Support

| Era | Status | Support |
|-----|--------|---------|
| Pre-1980s | Invisible; expected | None |
| 1980s | Beginning recognition | First support groups |
| 1990s | Research on caregiver burden | Limited programs |
| 2000s | Caregiver as patient too | Medical recognition |
| 2010s | Policy attention grows | RAISE Act, programs |
| 2020s | COVID exposes needs | Increased attention |

### Key Caregiver Milestones

| Year | Development |
|------|-------------|
| 1988 | First AARP caregiver report |
| 1993 | Family and Medical Leave Act |
| 2000 | National Family Caregiver Support Program |
| 2006 | Lifespan Respite Care Act |
| 2018 | RAISE Family Caregivers Act |
| 2022 | National Strategy to Support Family Caregivers |

## Policy History

### Federal Policy Timeline

| Year | Policy | Significance |
|------|--------|--------------|
| 1974 | National Institute on Aging established | Federal research capacity |
| 1986 | Alzheimer's Disease and Related Dementias Research Act | Dedicated research authority |
| 1990 | Americans with Disabilities Act | Some protections for dementia |
| 2011 | National Alzheimer's Project Act | Comprehensive strategy required |
| 2018 | BOLD Infrastructure for Alzheimer's Act | Public health approach |
| 2020 | Medicare adds cognitive assessment benefit | Detection emphasis |

### State Policy Development

| Period | Focus |
|--------|-------|
| 1980s | Nursing home regulation |
| 1990s | Assisted living emergence |
| 2000s | Adult day service standards |
| 2010s | Dementia training requirements |
| 2020s | Dementia-friendly community initiatives |

## Lessons from History

### What History Teaches

| Lesson | Application |
|--------|-------------|
| Disease requires advocacy | Patient/family voice essential |
| Research takes time | Decades from discovery to treatment |
| Care matters alongside cure | Quality of life interventions |
| Caregivers need support | Hidden burden must be addressed |
| Policy lags science | Continued advocacy needed |
| One paradigm isn't enough | Diversify research approaches |

### Historical Barriers Overcome

| Barrier | How Addressed |
|---------|---------------|
| "Just normal aging" | Scientific evidence and advocacy |
| Stigma | Disclosure, education campaigns |
| Minimal funding | Sustained advocacy, congressional champions |
| Neglect of caregivers | Research on burden, policy attention |
| Family isolation | Support groups, Alzheimer's Association |

### Persistent Challenges

| Challenge | Historical Roots |
|-----------|------------------|
| No cure | Complex disease biology |
| Underdiagnosis | Primary care capacity |
| Care fragmentation | Siloed healthcare system |
| Inadequate support | Medicare's acute care focus |
| Research failures | Single-paradigm dominance |

---

## Document Navigation

- Previous: [Current State](02-current-state.md)
- Next: [Root Causes](04-root-causes.md)
